LH is Phase II, it has to be completed. Then Phase 3 designed and protocols submitted, this will have to be a large trial, which should still be able to be enrolled quickly. However we are talking end of 2021 at the earliest. Maybe Q1 2022.
As I said EUA and CD16 do not mix. its one or the other. I prefer EUA. Because other countries will follow.
I suspect NP using "Conditional EUA" as a placeholder until he gets CD16 underway, which in my opinion they should already be at. However, if he states they filed a "Conditional EUA" it buys a few more weeks. Then we will never hear of it again and they will announce CD16 a couple of weeks away from first patient.
Cytodyn's best bet is to sell to a Country that has a need for a solution right now. This would be a Country that does not follow the US FDAs lead. That is where he should have started concentrating efforts two weeks ago.
News 
Market Data 
Discover 
AI
